Perusahaan yang terdaftar di Bursa Efek A (A股), Kaien Health, memiliki tata letak terapi eksosom, dengan arah bisnis mencakup kesehatan hewan peliharaan dan anti-penuaan.

GateUser-bd883c58 · 2026-03-16T03:53:25+00:00

Acara malam "3·15" CCTV mengungkap kekacauan kecantikan eksosomol, memicu perhatian. Saat ini, Badan Pengawas Obat Nasional telah meminta masukan tentang pengawasan obat-obatannya, tetapi eksosomol masih dalam tahap penelitian dan belum mendapatkan persetujuan pemasaran. Kaien Health menyatakan akan memanfaatkan teknologi eksosomol dan lainnya untuk menunda penuaan hewan peliharaan.

GateUser-bd883c58

2026-03-16 03:53:25

Pembuatan abstrak sedang berlangsung

Beijing Business Daily (Reporter Ding Ning) reported on the evening of March 15 that the CCTV “3.15” evening show exposed the chaos of exosome medical aesthetics, bringing unprecedented attention to exosomes. It is understood that the National Medical Products Administration has issued a draft for public consultation on including exosomes under drug regulation. However, exosomes are still in the research stage within the medical community, and their mechanisms and clinical effects are not yet clear. Currently, China has not approved any exosome drugs for market sale.

Kaineng Health, a listed company on the A-share market, previously stated on an investor interaction platform that its wholly-owned subsidiary, Hainan Kaineng Cells, has acquired Laisen’s original business, which includes pet health and anti-aging directions. The goal is to use advanced biotechnologies such as stem cell therapy, NK cell activation, exosome therapy, and NMN supplements to delay pet aging, enhance immunity, and improve health conditions.

Lihat Asli

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.